Replies to post #306488 on Avid Bioservices Inc (CDMO)

[biopharm]

Publication date Jul 4, 2017
Filing date Mar 13, 2014
Priority date Mar 15, 2013

Filing date synchs up to March 2014 when some unusual large tading days for Peregrine

[JJ1223]

Bayer : Patent Issued for Gla Domains as Targeting Agents (USPTO 9694048)

Bayer is scheduled to run a combo trial with Bavi through NCCN. Based on that, I assume they done a complete analysis on Bavituximab/PS. Today we see a Bayer patent filed the GLA domain protein that targets PS on the outside of the cell. This is an interesting development, and ties Peregrine, NCCN, and Bayer together
In the future development of PS Targeting.
My guess would be that PPHM is now an active take over target for Bayer. Make no mistake, this patent is a strong validation of PS in the future fight against disease. Whatever the result, we may hear something soon.

[biopharm]

BAYER started filing in March 2014 ...Maxine and Terry (St Louis top researchers of Terry possible ties to KCM )

http://patents.justia.com/inventor/maxine-bauzon


http://psioxus.com/cubeportfolio/dr-terry-hermiston/


Terry W Hermiston

PhD
Site Head, Bayer HealthCare US Innovation Center, VP Biologics Research
Bayer HealthCare , Leverkusen · Bayer HealthCare Pharmaceuticals

Top co-authorsView all

William SM Wold
44.72 (16)Saint Louis University

Ann E Tollefson
38.14 (11)Saint Louis University

Richard N Harkins
37.39 (9)Bayer

Kerry D Fisher
)University of Oxford

Fang Jin

https://www.researchgate.net/profile/Terry_Hermiston